Ben Derman, MD, discussed results from a trial investigating minimal residual disease–guided discontinuation of maintenance therapy in patients with multiple myeloma.
Ben Derman, MD, assistant professor of medicine at the University of Chicago Medical Center, discussed results from a trial investigating minimal residual disease (MRD)-guided discontinuation of maintenance therapy in patients with multiple myeloma.
The prospective MRD2STOP trial (NCT04108624) enrolled 38 patients who had complete responses to therapy and MRD negativity at the 10-6 threshold after 1 year of maintenance and permitted them to stop maintenance therapy. At 15 months follow-up, only 2 patients had progression, both of whom only had biochemical disease progression, and there were no deaths. Five patients had a resurgence of MRD positivity, including the 2 who progressed.
The study employed an exploratory 10-7 MRD threshold based on filtered CD138-positive cells, and 4 out of the 5 patients who lost MRD negativity at 10-6 after discontinuation had detectable disease at 10-7 before discontinuing therapy. Derman says this suggests that patients who have detectable disease at this higher threshold may be poor candidates for discontinuing therapy, whereas others appear to be able to safely discontinue their maintenance regimen with a lower risk of recurrence.
TRANSCRIPTION:
0:08 | We only have 15 months of follow-up so far on the study, but of the 38 patients who enrolled in discontinuation, we had 2 who had disease progression, 1 at 12 months, 1 at 18 months, and both were what we call biochemical progression. They didn't have bone disease, they didn't have new fractures, and these were patients that just had lab parameters showing progression. Fortunately, we've had 0 deaths. Of those 38 patients, just to come back to that, we had 5 patients who had MRD resurgence at 10-6, meaning they went from MRD negative to MRD positive at some point in this study. Only 2 of those 5 patients had disease progression, like I just mentioned.
What's interesting about this is the fact that 4 out of those 5 patients who had MRD resurgence were found to have detectable disease using our 10-7 assay…. That suggests that this 10-7 assay is not only feasible but may be able to tell us who should not actually discontinue, because if you have a detectable disease on that assay, it might be telling us that something is not right here. There's still some small amount of disease that we wouldn't have been able to detect using the 10-6 assay.
Axatilimab Shows Responses With Tolerable Safety in Recurrent/Refractory cGVHD
December 11th 2023Axatilimab induced rapid and durable responses with an acceptable toxicity profile at all doses analyzed with highest efficacy observed at the 0.3-mg/kg dose in patients with recurrent or refractory chronic graft-vs-host disease.
Read More
Single and Dual-Target D8 CAR T Cells Show Tolerability, Efficacy in R/R MM
December 10th 2023Investigators in the MCARTY study reported safety and high response rates in a small number of patients with relapsed/refractory multiple myeloma who received chimeric antigen receptor T-cell therapy designed with a new process to target the D8 binder, meant to improve efficacy in targeting BCMA.
Read More
Real-World Analysis Shows Similar Safety, Efficacy With Teclistamab in RRMM
December 9th 2023The retrospective analysis demonstrated comparable outcomes with teclistamab from the phase 2 MajesTEC-1 trial, highlighting the need for close monitoring and supportive care in patients treated for their relapsed or refractory multiple myeloma.
Read More